

The Medical Letter[®]

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

Correction: In Brief: Delayed-Release

Risedronate (*Atelvia*) p 52

Important Copyright Message

The Medical Letter[®] publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)

or call customer service at: 800-211-2769

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter publications are protected by US and international copyright laws.
Forwarding, copying or any other distribution of this material is strictly prohibited.
For further information call: 800-211-2769

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 53 (Issue 1367)
June 27, 2011

www.medicalletter.org

Correction: In Brief: Delayed-Release Risedronate (Atelvia) (Med Lett Drugs Ther 2011; 53:24)

The In-Brief article on delayed-release risedronate in issue 1360 included a statement that alendronate is currently the only bisphosphonate available generically. That would have been accurate if we had added "that is FDA-approved for treatment of osteoporosis." Etidronate (*Didronel*, and others), which was the first bisphosphonate used to treat osteoporosis ([Medical Letter 1990; 32:111](#)) but was never approved for such use by the FDA, is also available generically. It is approved for treatment of Paget's disease and for prevention and treatment of heterotopic ossification following hip replacement and in spinal-cord injured patients.

The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.

CONSULTING EDITOR: Brinda M. Shah, Pharm.D.

CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
Jules Hirsch, M.D., Rockefeller University
David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre
Richard B. Kim, M.D., University of Western Ontario
Hans Meinertz, M.D., University Hospital, Copenhagen
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Jordan W. Smoller, M.D., Sc.D., Harvard Medical School
Neal H. Steigbigel, M.D., New York University School of Medicine
Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University

SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School

MANAGING EDITOR: Susie Wong

ASSISTANT MANAGING EDITOR: Liz Donohue

PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona
FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski
DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino
VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
Web Site: www.medicalletter.org
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):
1 year - \$98; 2 years - \$189;
3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.

E-mail site license inquiries to:
info@medicalletter.org or call 800-211-2769 x315.
Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

Copyright 2011. ISSN 1523-2859